Literature DB >> 16423273

Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan.

Yoshikazu Inoue1, Koh Nakata, Toru Arai, Ryushi Tazawa, Emi Hamano, Toshihiro Nukiwa, Koichiro Kudo, Naoto Keicho, Nobuyuki Hizawa, Etsuro Yamaguchi, Ryosuke Eda, Kazunori Oishi, Yuuka Maeda, Yukiko Koreeda, Naohiko Kodo, Mitsunori Sakatani.   

Abstract

Idiopathic pulmonary alveolar proteinosis (IPAP) is a rare disease characterized by excessive amounts of lipoproteinaceous material in the alveolus. This report presents an interim analysis of nationwide epidemiological data from Japanese patients with pulmonary alveolar proteinosis, and the roles of serum markers for IPAP. (i) The nationwide demographic data from 166 Japanese patients with IPAP are shown. The female to male ratio was 1:2, and the average age was 51 +/- 14 years old (age range: 15-79 years) at registration or diagnosis. A total of 30% of patients with IPAP have a poor clinical course. In total, 30% of patients were treated with whole lung lavage therapy (WLL). Under WLL, the patients significantly improved in the short term, but 40% of the patients who underwent WLL worsened again. A new strategy such as granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for intractable PAP is required. (ii) The correlation of serum KL-6, carcinoembryonic antigen, surfactant proteins D and A, and LDH with disease severity suggests their potential as disease markers. In contrast, serum anti-GM-CSF antibody did not correlate with disease severity, but is a specific marker for the diagnosis of IPAP. The combined measurements of the serum markers may well prove very useful for both the diagnosis and the management of IPAP patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423273     DOI: 10.1111/j.1440-1843.2006.00810.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  A case of autoimmune pulmonary alveolar proteinosis with fluctuating lung shadows in parallel with cigarette smoke burden.

Authors:  Takahashi Ayumu; Yamaguchi Etsuro; Yonezawa Toshiyuki; Kosaka Kenshi; Matsubara Ayako; Nishimura Masaki; Tanaka Hiroyuki; Yokoe Norihito; Kubo Akihito
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

2.  A case of autoimmune pulmonary alveolar proteinosis with severe respiratory failure treated with segmental lung lavage and oral statin therapy.

Authors:  Tomotsugu Takano; Keisuke Takeda; Satoshi Nakamura; Genta Akiyama; Nobuhisa Ando; Masashi Komori
Journal:  Respir Med Case Rep       Date:  2022-06-06

3.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

4.  Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis.

Authors:  Jiuwu Bai; Huiping Li; Jingyun Shi; Jinfu Xu; Xia Li; Weijun Cao; Haiqing Chu; Jinming Liu; Beilan Gao
Journal:  Biomed Rep       Date:  2013-02-20

5.  Long-term follow-up of whole lung lavage in patients with pulmonary alveolar proteinosis.

Authors:  Xiaoyan Zhou; Guochu Lu; Zhen Yu; Fei Gao; Tao Bian
Journal:  Exp Ther Med       Date:  2014-06-18       Impact factor: 2.447

6.  Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey.

Authors:  Ji An Hwang; Joo Han Song; Jung Hoon Kim; Man Pyo Chung; Dong Soon Kim; Jin Woo Song; Young Whan Kim; Sun Mi Choi; Seung Ick Cha; Soo Taek Uh; Choon-Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Yangjin Jegal; Hyun Kyung Lee; Jong Sun Park; Moo Suk Park
Journal:  BMC Pulm Med       Date:  2017-11-21       Impact factor: 3.317

7.  Assessment and management of pulmonary alveolar proteinosis in a reference center.

Authors:  Ilaria Campo; Francesca Mariani; Giuseppe Rodi; Elena Paracchini; Eric Tsana; Davide Piloni; Isabella Nobili; Zamir Kadija; Angelo Corsico; Isa Cerveri; Claudia Chalk; Bruce C Trapnell; Antonio Braschi; Carmine Tinelli; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2013-03-13       Impact factor: 4.123

8.  GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders.

Authors:  Matthias Griese; Ralf Zarbock; Ulrich Costabel; Jenna Hildebrandt; Dirk Theegarten; Michael Albert; Antonia Thiel; Andrea Schams; Joanna Lange; Katazyrna Krenke; Traudl Wesselak; Carola Schön; Matthias Kappler; Helmut Blum; Stefan Krebs; Andreas Jung; Carolin Kröner; Christoph Klein; Ilaria Campo; Maurizio Luisetti; Francesco Bonella
Journal:  BMC Pulm Med       Date:  2015-08-12       Impact factor: 3.317

Review 9.  Natural Autoantibodies in Chronic Pulmonary Diseases.

Authors:  Kiyoharu Fukushima; Kazuyuki Tsujino; Shinji Futami; Hiroshi Kida
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

10.  Removal of lung lavage fluid during whole-lung lavage using biphasic cuirass ventilation chest percussion in a patient with autoimmune pulmonary alveolar proteinosis.

Authors:  Kei Nakamura; Satoko Omura; Koichiro Kajiura; Masanobu Ishigaki
Journal:  Lung India       Date:  2019 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.